Search Results - "PURINGTON, Lauren C"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot by Levitt, Erica S, Purington, Lauren C, Traynor, John R

    Published in Molecular pharmacology (01-03-2011)
    “…Organization of G protein-coupled receptors and cognate signaling partners at the plasma membrane has been proposed to occur via multiple mechanisms, including…”
    Get more information
    Journal Article
  2. 2

    Fumaroylamino-4,5-epoxymorphinans and Related Opioids with Irreversible μ Opioid Receptor Antagonist Effects by Moynihan, Humphrey A, Derrick, Ian, Broadbear, Jillian H, Greedy, Benjamin M, Aceto, Mario D, Harris, Louis S, Purington, Lauren C. S, Thomas, Mark P, Woods, James H, Traynor, John R, Husbands, Stephen M, Lewis, John W

    Published in Journal of medicinal chemistry (26-11-2012)
    “…We have previously shown that cinnamoyl derivatives of 14β-amino-17-cyclopropylmethyl-7,8-dihydronormorphinone and 7α-aminomethyl-6,14-endoethanonororipavine…”
    Get full text
    Journal Article
  3. 3

    Development and in Vitro Characterization of a Novel Bifunctional μ-Agonist/δ-Antagonist Opioid Tetrapeptide by Purington, Lauren C, Sobczyk-Kojiro, Katarzyna, Pogozheva, Irina D, Traynor, John R, Mosberg, Henry I

    Published in ACS chemical biology (16-12-2011)
    “…The development of tolerance to and dependence on opioid analgesics greatly reduces their long-term usefulness. Previous studies have demonstrated that…”
    Get full text
    Journal Article
  4. 4

    Pentapeptides Displaying μ Opioid Receptor Agonist and δ Opioid Receptor Partial Agonist/Antagonist Properties by Purington, Lauren C, Pogozheva, Irina D, Traynor, John R, Mosberg, Henry I

    Published in Journal of medicinal chemistry (10-12-2009)
    “…Chronic use of μ-opioid agonists has been shown to cause neurochemical adaptations resulting in tolerance and dependence. While the analgesic effects of these…”
    Get full text
    Journal Article
  5. 5

    Modulation of Opioid Receptor Ligand Affinity and Efficacy Using Active and Inactive State Receptor Models by Anand, Jessica P., Purington, Lauren C., Pogozheva, Irina D., Traynor, John R., Mosberg, Henry I.

    Published in Chemical biology & drug design (01-11-2012)
    “…Mu opioid receptor (MOR) agonists are widely used for the treatment of pain; however, chronic use results in the development of tolerance and dependence. It…”
    Get full text
    Journal Article
  6. 6

    Mixed κ/μ Opioid Receptor Agonists: The 6β-Naltrexamines by Cami-Kobeci, Gerta, Neal, Adrian P, Bradbury, Faye A, Purington, Lauren C, Aceto, Mario D, Harris, Louis S, Lewis, John W, Traynor, John R, Husbands, Stephen M

    Published in Journal of medicinal chemistry (26-03-2009)
    “…Ligands from the naltrexamine series have consistently demonstrated agonist activity at κ opioid receptors (KOR), with varying activity at the μ opioid…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Investigating interactions between mu and delta opioid receptors using bifunctional peptides by Purington, Lauren C. S

    Published 01-01-2011
    “…Morphine and other opioids exert their effects by activation of opioid receptors, which belong to the G protein-coupled receptor (GPCR) superfamily. Clinically…”
    Get full text
    Dissertation
  9. 9

    Investigating interactions between mu and delta opioid receptors using bifunctional peptides by Purington, Lauren C. S

    “…Morphine and other opioids exert their effects by activation of opioid receptors, which belong to the G protein-coupled receptor (GPCR) superfamily. Clinically…”
    Get full text
    Dissertation